# SES AI Corp: Form 10-Q for the period ended Jun 30, 2024

- Company: [SES AI Corp](/companies/ses.md) (CIK 1819142)
- Form: 10-Q
- Filed: 2024-07-30
- Accepted by EDGAR: Jul 30, 2024, 16:16 ET
- Period: 2024-06-30
- Accession: 0001819142-24-000033
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1819142/000181914224000033/ses-20240630x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1819142/000181914224000033/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2024-04-01 to 2024-06-30 | $15.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2024-01-01 to 2024-06-30 | $26.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2024-04-01 to 2024-06-30 | −$24.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2024-01-01 to 2024-06-30 | −$45.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2024-04-01 to 2024-06-30 | $96.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2024-01-01 to 2024-06-30 | $293.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-04-01 to 2024-06-30 | −$19.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2024-01-01 to 2024-06-30 | −$35.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-04-01 to 2024-06-30 | −$0.06 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2024-01-01 to 2024-06-30 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-04-01 to 2024-06-30 | −$0.06 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2024-01-01 to 2024-06-30 | −$0.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-04-01 to 2024-06-30 | 320,833,854 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2024-01-01 to 2024-06-30 | 319,812,287 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2024-01-01 to 2024-06-30 | −$31.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2024-01-01 to 2024-06-30 | $10.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2024-06-30 | $54.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-06-30 | $310.1m | us-gaap:AssetsCurrent |
| Total assets | at 2024-06-30 | $368.4m | us-gaap:Assets |
| Current liabilities | at 2024-06-30 | $14.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-06-30 | $36.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2024-06-30 | $331.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 29,860 characters.

*The following discussion and analysis provides information which our management believes is relevant to an assessment and understanding of our consolidated results of operations and financial condition. The following discussion and analysis should be read in conjunction with the accompanying unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2024 and the related notes included in this Quarterly Report on Form 10-Q and our audited consolidated financial statements as of and for the year ended December 31, 2023 and the related notes contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 27, 2024 (the “2023 Annual Report”). This Quarterly Report on Form 10-Q includes forward-looking statements. These forward-looking statements within the meaning of the federal securities law are based on our current expectations and beliefs concerning future developments and their potential effects on us. These forward-looking statements are not statements of historical fact and may include statements regarding possible or assumed future results of operations. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Factors that might cause or contribute to such forward-looking statements include, but are not limited to, those set forth in Part II, Item 1A of this Quarterly Report on Form 10-Q and in Item 1A. Risk Factors in the 2023 Annual Report. Unless the context otherwise requires, references in this section to “the Company,” “we,” “us” and “our” refer to the business and operations of SES Holdings Pte. Ltd. (“Old SES”) and its consolidated subsidiaries prior to the Business Combination and to SES AI Corporation and its consolidated subsidiaries following the Closing. References in this section to our future plans that indicate the timing of when we expect such plans to be completed by a certain year mean at any point during that year.*

### Overview

We are a pre-commercialization stage company engaged in the development and production of high-performance, Lithium-Metal (“Li-Metal”) rechargeable battery technologies for electric vehicles (“EVs”), Urban Air Mobility (“UAM”), which encompasses electric vehicle take-off and landing (“eVTOL”) technology, and other applications. Our differentiated battery technology has been designed to combine the high energy density of Li-Metal with the large-scale manufacturability of conventional Lithium-ion (“Li-ion”) batteries to help promote the transition from the global dependence on fossil fuel-based automotive vehicles to clean and efficient EVs in order to enable a new era of electric transportation on land and in the air.

SES AI’s mission is to power a new era of electric transportation on land and in the air with Li-Metal batteries. We believe Li-Metal is the “end game” for electric transportation energy storage with its potential for step-change in energy density compared to state-of-the-art Li-ion. Our team has dedicated the past decade to developing a comprehensive and proprietary Li-Metal battery technology platform, including high concentration solvent-in-salt electrolyte, ultra-thin wide format lithium anode, protective anode coating, and novel cell engineering processes that are based on scalable Li-ion manufacturing but address unique Li-Metal challenges. As we build more automotive large capacity Li-Metal cells and generate more data, artificial intelligence (“AI”) becomes an increasingly integral part in material development, battery health monitoring and incident prediction.

There are four pillars to our mission.

#### 1\. Electric Vehicles (EV)

Since our founding, EV has always been our core focus. In 2012, we transitioned away from solid state Li-Metal, so our Li-Metal batteries could operate at room temperature and be manufactured at large scale. In 2015, we received the first strategic investment from General Motors. In 2021, we signed what we believe to be the world’s first automotive A-sample Li-Metal joint development agreements (JDAs) with GM, Hyundai and Honda, all of whom made strategic investments in our company. In 2023, we signed what we believe to be the world’s first automotive B-sample Li-Metal JDA with a major global automaker. In 2024, we extended our JDA agreement with Hyundai to conduct further research and development activities in order to achieve production of B-sample batteries. As of June 30, 2024, we operate three A-sample lines and we are in the process of building two B-sample lines.

We have made significant progress in large 50Ah and 100Ah automotive Li-Metal cell manufacturing. We have addressed key manufacturing challenges in ultra-thin wide format lithium anode, powder and metal bur issues in lithium anode punching, high concentration electrolyte scale-up, and other quality and safety related issues in automotive large Li-Metal cell manufacturing. We have performed inhouse testing on these 50Ah and 100Ah Li-Metal A-sample cells and shared testing data with our JDA original equipment manufacturer (OEM) partners, as well as shipped these A-sample cells to other third parties and OEMs for their further performance and safety testing.

#### 2\. Urban Air Mobility (UAM)

We believe that B-sample in EV is almost equivalent to commercial production for UAM. We believe that UAM is a perfect fit for Li-Metal and will require little additional development now that we have reached EV B-sample status. UAM frequently operates on a fleet business model where the key business metrics are cost per passenger per mile, with weight being a paramount factor to costs. We believe that the step-change gravimetric energy density that Li-Metal can potentially offer means that an aircraft has the potential to carry twice the number of passengers, or twice the payload for cargo applications, or fly twice the distance, which has the potential to significantly improve the profitability of UAM operators. We are converting one of our EV A-sample lines to be dedicated to UAM cell production by the end of 2024.

#### 3\. Artificial Intelligence (AI)

We started two AI programs out of necessity, due to the need to provide a high level of safety in the field and the need to further accelerate our future roadmap for material development.

We seek to provide a high level of safety in the field and we are leveraging our automotive 50Ah and 100Ah cell production volume and quality data to train our Avatar AI. Our Avatar AI prediction accuracy increased from less than 60% in 2022, to 92% in 2023, and we expect it to reach 95% accuracy by the end of 2024. Our ultimate goal is to be able to reach near 100% safety in the field, which we believe will be paramount to both EV and UAM OEMs.

We are also developing new AI models designed to screen a vast universe of small molecules for potential electrolyte solvent candidates. We have also built an electrolyte foundry designed to provide high throughput synthesis and testing of these materials.

#### 4\. Sustainability

We are executing several initiatives to improve the environmental sustainability of our business, and to reduce cost and ensure traceability of our Li-Metal battery supply chain. The technological innovations include dry electrode that can significantly reduce our electricity consumption and CO2 and chemical solvent emissions, and recycling of Li-Metal that allows us to build a new supply chain with better traceability and robustness. Recently, we also announced SES Cares, where we power advanced drones with our Li-Metal A-samples and B-samples to collect field data to train Avatar AI, at the same time, partner with operations such as forest fire monitoring and marine animal protection.

### Outlook

We believe that 2024 will be a key year in the commercialization of Li-Metal batteries for automotive applications. We continue to focus on EV B-sample JDAs including building and operating B-sample lines, improving cell practical safety and accelerating future roadmap electrolyte development; building and shipping cells to UAM OEM partners; and improving Avatar AI prediction accuracy by deploying Avatar infrastructure and training it across a wide range of data.

After B-Sample, we plan to transition to C-Sample in 2026, which we then expect to enable us to commence commercial production of our technology in 2027. We expect this transition to commercial production to lead to future research facilities and, eventually, commercial production manufacturing facilities in the United States, which will significantly increase our materials consumption and the rate of cash utilization over time.

### Results of Operations

#### Factors Affecting Operating Results

As of June 30, 2024, we have not generated any revenue from sales to customers to date through our one operating segment and have spent $15.6 million and $14.6 million on gross research and development activities during the three months ended June 30, 2024 and 2023, respectively, and $30.9 million and $26.3 million on gross research and development activities during the six months ended June 30, 2024 and 2023, respectively, which is prior to reimbursements received of $0.6 million and $8.3 million during the three months ended June 30, 2024 and 2023, respectively, and $4.1 million and $11.5 million during the six months ended June 30, 2024 and 2023, respectively, from our OEM partners under the JDAs. As a result, we have incurred net losses of $19.9 million and $12.9 million for the three months ended June 30, 2024 and 2023, respectively, and net losses of $35.5 million and $29.2 million for the six months ended June 30, 2024 and 2023, respectively. Our historical results may not be indicative of our future results for reasons that may be difficult to anticipate and our ability to generate revenue in the future that is sufficient enough to achieve profitability will depend largely on the successful development of our products. Accordingly, the drivers of our future financial results, as well as the components of such results, may not be comparable to our historical results of operations.

The following table sets forth our historical operating results for the periods indicated:

*(in thousands)*

| ​ ​ | ​ ​ Three Months Ended June 30, 2024 | ​ ​ | ​ ​ 2023 | ​ ​ ​ | ​ ​ $​% Change | ​ ​ | ​ ​ Change |
| --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Research and development | $15,057 | ​ | $6,347 | ​ | $8,710 | ​ | 137% |
| General and administrative | ​ 9,570 | ​ | ​ 12,924 | ​ | ​ (3,354) | ​ | (26)% |
| **Total operating expenses** | $24,627 | ​ | $19,271 | ​ | $5,356 | ​ | 28% |

*(in thousands)*

| ​ ​ | ​ ​ Six Months Ended June 30, 2024 | ​ ​ | ​ ​ 2023 | ​ ​ ​ | ​ ​ $​% Change | ​ ​ | ​ ​ Change |
| --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Research and development | $26,822 | ​ | $14,836 | ​ | $11,986 | ​ | 81% |
| General and administrative | ​ 19,076 | ​ | ​ 26,047 | ​ | ​ (6,971) | ​ | (27)% |
| **Total operating expenses** | $45,898 | ​ | $40,883 | ​ | $5,015 | ​ | 12% |

#### Research and Development

Research and development expenses consist primarily of costs incurred for salaries and personnel-related expenses, including performance-based bonus and stock-based compensation expense, for scientists, experienced engineers and technicians, expenses for materials and supplies used in product research and development, process engineering efforts and testing, as well as payments to consultants, depreciation, and allocated facilities and information technology costs. Additionally, payments received from the JDA agreements are treated as reimbursements to research and development expenses.

Research and development expenses for the three months ended June 30, 2024 increased $8.7 million, or 137%, to $15.1 million, compared with $6.3 million for the three months ended June 30, 2023. This increase was primarily driven by a $7.7 million decrease in credits to research and development expenses from decreased billings to our JDA partners for reimbursements due to the timing for finalizing our JDA amendment terms, a $1.6 million increase in personnel costs mainly attributable to our growth in headcount to support our operations, a $0.9 million increase in facility related costs such as rent, utilities and depreciation expenses mainly attributable to the new electrolyte foundry, and a $0.5 million increase in software development expenses due to university research agreements. The resulting higher expenses were partially offset by a $1.6 million decrease in lab equipment and material supplies due to the termination of one of our pre-production facility leases, and a $0.6 million decrease in stock-based compensation attributable to employee departure and the conclusion of the amortization period for the earn-out restricted shares by the third quarter of 2023.

Research and development expenses for the six months ended June 30, 2024 increased $12.0 million, or 81%, to $26.8 million compared with $14.8 million for the six months ended June 30, 2023. This increase was primarily driven by a $7.3 million decrease in credits to research and development expenses from billings for reimbursement from our JDA partners due to the timing for finalizing our JDA amendment terms, a $4.7 million increase in personnel costs mainly attributable to our growth in headcount to support our operations, a $1.8 million increase in facility related costs such as increased rent, utilities and depreciation expenses mainly attributable to the new electrolyte foundry, and a $0.5 million increase in professional services. These increases were partially offset by a $1.3 million decrease in lab equipment and material supplies due to the termination of one of our pre-production facility leases and a $1.0 million decrease in stock-based compensation attributable to employee departure and the conclusion of the amortization period for the earn-out restricted shares by the third quarter of 2023.

#### General and Administrative

General and administrative expenses consist primarily of costs incurred for salaries and personnel-related expenses, including bonus and stock-based compensation expense, for our finance, legal and human resource functions, expenses for director and officer insurance, outside contractor and professional service fees, audit and compliance expenses, legal, patent-related costs, accounting and other advisory services, as well as allocated facilities and information technology costs, including depreciation. Upon commencement of commercial operations, we also expect to incur customer and sales support and advertising costs.

General and administrative expenses for the three months ended June 30, 2024 decreased $3.4 million, or 26%, to $9.6 million, compared with $12.9 million for the three months ended June 30, 2023. This decrease was primarily driven by a decrease of $1.9 million of stock-based compensation expense that related to the conclusion of the amortization period for the earn-out restricted shares by the third quarter of 2023, and a $0.4 million decrease in insurance expense due to lower premiums incurred to cover potential liabilities under our indemnification obligations to our directors and certain officers of the Company.

General and administrative expenses for the six months ended June 30, 2024 decreased $7.0 million, or 27%, to $19.1 million, compared with $26.0 million for the six months ended June 30, 2023. This decrease was primarily driven by a decrease of $3.2 million of stock-based compensation expense that related to the conclusion of the amortization period for the earn-out restricted shares by the third quarter of 2023, a $1.4 million decrease in accounting related expense due to the reduction in audit fees from the prior period resulting from a more efficient reporting process, a $1.0 million decrease in insurance expense due to lower premiums incurred to cover potential liabilities under our indemnification obligations to our directors and certain officers of the Company compared to the prior year period, and a $1.0 million decrease in legal expenses primarily due to the higher cost incurred to support compliance as a large accelerated filer in 2023.

### Non-Operating Items

#### Interest Income

Interest income primarily consists of interest earned on our cash and cash equivalents and marketable debt securities, which are primarily invested in money market funds and U.S. treasury securities, and accretion income from the U.S. treasury securities.

During the three and six months ended June 30, 2024, we had interest income of $4.0 million and $8.2 million, respectively, compared with $4.1 million and $8.3 million for the three and six months ended June 30, 2023, respectively. The $0.1 million decreases from each of the three and six months ended June 30, 2023 to each of the three and six months ended June 30, 2024 were due to lower investment balances primarily arising from cash used in operations.

#### Change in Fair Value of Earn-Out Liabilities

During the three and six months ended June 30, 2024, we incurred a gain of $1.4 million and $2.3 million, respectively, associated with the change in fair value of the Sponsor Earn-Out liabilities compared with a gain of $2.9 million and $3.5 million, respectively, for the three and six months ended June 30, 2023. With the fair value of the Sponsor Earn-Out liabilities tied to the Company’s stock price, continued volatility in the stock price or changes in the expected term could result in further gains or losses resulting from the change in fair value. Refer to “Note 8 – Sponsor Earn-Out Liabilities” to the unaudited interim condensed consolidated financial statements for additional information.

#### Miscellaneous Income (Expense), Net

During the three months ended June 30, 2024, we had miscellaneous expense of $0.6 million, compared with miscellaneous expense of $0.4 million for the three months ended June 30, 2023. This $0.2 million increase in miscellaneous expense was an increase in the loss on foreign currency translation offset by an increase in fair value of equity investments.

During the six months ended June 30, 2024, we had miscellaneous income of $0.3 million, compared with miscellaneous income of $0.4 million for the six months ended June 30, 2023. This $0.1 million decrease in miscellaneous income was the result of an increase in the loss on foreign currency translation offset by an increase in fair value of equity investments.

#### Provision from Income Taxes

The provision for income taxes for the three and six months ended June 30, 2024 increased to $0.1 million and $0.3 million, compared to $0.3 million and $0.5 million for the three and six months ended June 30, 2023, respectively, primarily due to local taxes in the foreign jurisdictions in which the Company operates.

### Liquidity and Capital Resources

As of June 30, 2024, we had total cash and cash equivalents of $54.8 million and investments in marketable debt and equity securities of $239.9 million. As a pre-commercialization stage research and development company, the net operating losses we have incurred since inception are consistent with our strategy and budget.

As a result of the capital-intensive nature of our business, we expect to sustain substantial operating expenses, without generating sufficient revenues to cover expenditures, for a number of years. To date, we have funded our operations through a combination of proceeds from the Business Combination private investments in public entity and funding received through the sales of our redeemable convertible preferred stock. These funds are expected to finance our principal sources of liquidity and ongoing costs, such as research and development relating to our Li-Metal batteries and the construction of additional manufacturing facilities. In the future, if we are not able to fund our operations from cash flows generated from anticipated product sales, we expect that we will need to raise additional funds through a variety of possible methods, including, but not limited to, entry into joint ventures or other strategic arrangements, issuance of equity, equity-related or debt securities or through obtaining credit from financial institutions, as well as anticipated future revenue from product sales.

We believe that our cash on hand and marketable securities will be sufficient to meet our working capital and capital expenditure requirements for a period of at least 12 months from the date of filing this Quarterly Report on Form 10-Q, and also sufficient to fund us to commercialization. However, additional funding may be required for a variety of reasons, including opportunities to build an integrated supply chain in the United States and delays in expected development of our Li-Metal battery cells. Our ability to successfully develop our products, commence commercial operations and expand our business will depend on many factors, including our working capital needs, the availability of equity and/or debt financing and, over time, our ability to generate positive cash flows from operations.

### Summary of Cash Flows

The following table provides a summary of our cash flow data for the periods indicated:

*(in thousands)*

| ​ ​ Cash (used in) provided by: | ​ ​ Six Months Ended June 30, 2024 ​ ​ | ​ ​ ​ | ​ ​ 2023 ​ ​ |
| --- | --- | --- | --- |
| Operating activities | $(31,071) | ​ | $(30,865) |
| Investing activities | ​ 547 | ​ | ​ (23,798) |
| Financing activities | ​ 128 | ​ | ​ 77 |
| Effect of exchange rate changes on cash | ​ (501) | ​ | ​ (595) |
| **Net decrease in cash, cash equivalents and restricted cash** | $(30,897) | ​ | $(55,181) |

### Operating Activities

Our cash flows used in operating activities to date have primarily comprised research and development and general and administrative activities as discussed above. As we continue to ramp up hiring for research and development headcount to accelerate our engineering efforts, we expect our cash used in operating activities to increase significantly before we start to generate any material cash inflows from our operations.

Net cash used in operating activities of $31.1 million for the six months ended June 30, 2024 was primarily attributable to net loss of $35.5 million, as adjusted for stock-based compensation expense of $9.6 million, accretion income from marketable securities of $3.9 million, depreciation and amortization of $3.7 million, a gain on change in fair value of Sponsor Earn-Out liabilities of $2.3 million, other adjustments to net loss of $1.5 million, and a $1.2 million working capital outflow. The working capital outflow was primarily driven by a $2.5 million increase in prepaids and other assets. The increase in prepaids and other assets was primarily due to advance payments made for equipment purchases pursuant to our JDA agreements and prepaid costs related to software development. Additionally, a $1.8 million decrease in accrued expenses and other liabilities was due to the timing of legal fees and equipment purchases also contributed to the working capital outflow. The outflow was partially offset by a $3.3 million receipt from the related party.

Net cash used in operating activities of $30.9 million for the six months ended June 30, 2023 was primarily attributable to net loss of $29.2 million, as adjusted for stock-based compensation expense of $13.8 million, accretion income from marketable securities of $5.9 million, a gain in change in fair value of Sponsor Earn-Out Liability of $3.5 million, depreciation and amortization of $2.3 million and a $8.1 million working capital outflow. The working capital outflow was primarily driven by a $6.6 million increase in prepaids and other assets, and a $3.8 million decrease in accrued expensed and other liabilities, partially offset by a $2.3 million increase in accounts payable. The increase in prepaids and other assets was primarily due to amounts due from JDA partners, the renewal of an insurance contract to cover potential liabilities under our indemnification obligations to our directors and certain officers, and prepaid costs related to software development. The decrease in accrued expenses and other liabilities was primarily due to the release of deferred liabilities related to JDAs. The increase in accounts payable was primarily due to the extended timing of our payments.

### Investing Activities

Net cash provided by investing activities was $0.5 million for the six months ended June 30, 2024, compared to net cash used in investing activities of $23.8 million for the six months ended June 30, 2023.

*Purchases and Maturities of Investments –* Net proceeds from investments in marketable debt and equity securities were $11.0 million for the six months ended June 30, 2024, compared to net purchases of investments in marketable debt and equity securities of $16.0 million during the six months ended June 30, 2023.

*Capital Spending –* Capital expenditures were $10.5 million and $7.8 million for the six months ended June 30, 2024 and 2023, respectively, and primarily related to the timing of purchases of lab machinery and equipment, lab tools and instruments related to our build out of production lines and facilities. We expect capital expenditures for the rest of 2024 to increase compared with the corresponding periods in 2023 as we continue to invest in the build out of our fourth and fifth production lines and research and development facilities.

### Financing Activities

Net cash provided by financing activities was $0.1 million for the six months ended June 30, 2024 and 2023.

### Contractual Obligations and Commitments

The following table summarizes our material contractual obligations for cash expenditures as of June 30, 2024, and the periods in which these obligations are due:

*(in thousands)*

| ​ | ​ ​ Short Term | ​ ​ | ​ ​ Long Term | ​ ​ | ​ ​ Total |
| --- | ---: | --- | ---: | --- | ---: |
| Purchase obligations(1) | $39,177 | ​ | $2,678 | ​ | $41,855 |
| Operating lease obligations(2) | **​** 3,415 | ​ | **​** 11,169 | ​ | **​** 14,584 |
| Total | $42,592 | ​ | $13,847 | ​ | $56,439 |

(1) Purchase obligations include commitments derived from a JDA agreement, outstanding purchase orders, and supplier contracts of lab supplies and equipment.

(2) Operating lease obligations represent the fixed lease payments for the noncancelable lease term, fixed lease payments for optional renewal periods where the Company is reasonably certain the renewal option will be exercised, and variable lease payments that depend on an underlying index or rate in effect at lease commencement.

### Off-Balance Sheet Arrangements

As of June 30, 2024, we had a letter of credit issued by a financial institution totaling $0.6 million. The letter of credit relates to deposits the Company is required to maintain for one of its operating lease agreements. We have restricted cash that serves as collateral for this outstanding letter of credit that is included in other assets on our unaudited interim condensed consolidated balance sheet. No amounts have been drawn under the letter of credit.

### Recent Accounting Pronouncements

See “Note 2 – Basis of Presentation” of our accompanying unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2024 included in this Quarterly Report on Form 10-Q for more information about recent accounting pronouncements, the timing of their adoption, and their potential impact on our financial condition, results of operations and cash flows.

### Critical Accounting Estimates and Judgments

Our financial statements have been prepared in accordance with U.S. GAAP. In the preparation of these unaudited interim condensed consolidated financial statements, we are required to use judgment in making estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the unaudited interim condensed consolidated financial statements, as well as the reported expenses incurred during the reporting periods.

There have been no significant changes to our critical accounting policies or in the underlying accounting assumptions and estimates used in such policies from those disclosed in our annual consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2023.

### Other Information

The Company’s website is www.ses.ai. Information contained on the Company’s website is not part of this report. Information that we furnish to or file with the SEC, including the Company’s annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to, or exhibits included in, these reports are made available for download, free of charge, through the Company’s website as soon as reasonably practicable. The Company’s SEC filings, including exhibits filed therewith, are also available directly on the SEC’s website at www.sec.gov.

The Company may use its website as a distribution channel of material company information. Financial and other important information regarding the Company is routinely posted on and accessible through the Company’s website at www.ses.ai. Accordingly, investors should monitor this channel, in addition to following the Company’s press releases, SEC filings and public conference calls and webcasts. The contents of our website are not, however, a part of this report.

## Market risk

As filed, 330 characters.

There have been no significant changes to the Company’s market risk during the three months ended June 30, 2024. Refer to “Part II. Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2023 for a discussion of the Company’s exposure to market risk.

## Controls and procedures

As filed, 6,542 characters.

### Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our chief executive officer (“CEO”) and chief financial officer (“CFO”), we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2024, as such term is defined in Rules 13a-15(e) and 15d-15(e) under Securities Exchange Act of 1934, as amended (the “Exchange Act”). Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of June 30, 2024, our disclosure controls and procedures were not effective due to certain unremediated material weaknesses in our internal control over financial reporting, as discussed in more detail below.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis.

Notwithstanding the identified material weaknesses, management, with the participation of the principal executive officer and principal financial officer, believes the unaudited interim condensed consolidated financial information included in this Quarterly Report on Form 10-Q fairly represent in all material respects our financial condition, results of operations and cash flows at and for the periods presented in accordance with U.S. GAAP.

### Material Weaknesses

We previously identified a material weakness, as disclosed in our 2023 Annual Report. The Company did not design and maintain sufficient user access and monitoring controls to ensure appropriate segregation of duties and adequately restrict access to a financial application. As a result, automated and manual business process controls that are dependent on the affected IT general controls were also deemed ineffective, as they could have been adversely affected due to their reliance on information and configurations from the affected IT system.

Further, as previously disclosed, in the first quarter of 2024 we identified an additional material weakness in a review control because it failed to detect an error in the accounting for forfeitures of Earn-Out Restricted Shares upon a holder’s termination of employment.

The material weaknesses did not result in any material misstatements to our unaudited condensed consolidated financial statements or disclosures in any of the three months ended June 30, 2024 or 2023 included in this Quarterly Report on Form 10-Q, and our management believes the condensed consolidated financial information included in this Quarterly Report on Form 10-Q fairly represent in all material respects our financial condition, results of operations and cash flows for such periods in accordance with U.S. GAAP.

### Management’s Remediation Initiatives

We have developed detailed remediation plans, with appropriate executive sponsorship, to specifically address the material weaknesses. We have taken the following steps towards remediation of the identified material weaknesses and to enhance our internal control over financial reporting:

- We have hired professionally qualified accountants who have the appropriate level of expertise in the areas of accounting, financial reporting, and IT general controls.
- We have taken steps to enhance the design of existing control activities related to IT environment and implemented additional process-level control activities.
- We have restricted, and will continue to restrict, access to the financial application to ensure appropriate segregation of duties.
- We have designed updated processes and controls around change management monitoring to ensure that all changes have sufficient documentation and are reviewed by an authorized person.
- We have added, and will continue to maintain, an additional layer of internal review over the accounting of the Earn-Out Restricted Shares’ expense in relation to employees’ terminations and forfeitures.

### Remediation of Previously Reported Material Weakness

In response to the Sponsor Earn-Out liabilities material weakness, the Company executed a remediation plan in the first half of 2024. We provided training to our employees, hired new third-party valuation professionals and maintained sufficient and appropriate review documentation for the assessment of all the key assumptions and inputs used in the valuation of Sponsor Earn-Out liabilities. As a result, we have concluded that the material weakness related to valuation of Sponsor Earn-Out liabilities, previously reported in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on February 27, 2024, has been remediated as of June 30, 2024.

We have expended, and will continue to expend, a substantial amount of effort and resources for the remediation and improvement of our internal control over financial reporting. We will continue to work on improvements to our internal controls during 2024 as we assess and evaluate the controls intended to remediate the material weaknesses. Until the material weaknesses included in the “Material Weaknesses” section above are remediated, we plan to continue to perform analytical procedures to ensure that our consolidated financial statements are prepared in accordance with GAAP.

### Changes in Internal Control over Financial Reporting

Other than the actions taken as described in “Management’s Remediation Initiatives” and “Remediation of Previously Reported Material Weakness” above to improve the Company’s internal control over financial reporting, there have been no changes in our internal control over financial reporting during the most recent fiscal quarter that materially affected, or which are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 689 characters.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors disclosed in “Part I, Item 1A” of our Annual Report on Form 10-K for the year ended December 31, 2023, and the other reports that we have filed with the SEC. Any of the risks discussed in such reports, as well as additional risks and uncertainties not currently known to us or that we currently deem immaterial, could materially and adversely affect our results of operations, financial condition or prospects. During the period covered by this Quarterly Report on Form 10-Q, there have been no material changes in our risk factors as previously disclosed.

Filed Jul 30, 2024.
Source: SEC EDGAR, the filing index for accession 0001819142-24-000033. Last ingested by Listed: Nov 13, 2026, 16:22 ET. No prices; not investment advice.
